The non-neuronal cholinergic system in health and disease

Pharmacology

Volumn 92, Issue 5-6, 2014, Pages 286-302

  Beckmann, Janet ^a   Lips, Katrin Susanne ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Acetylcholine; Acetylcholinesterase; Choline acetyltransferase; Muscarinic receptors; Nicotinic receptors; Non neuronal cholinergic system; Organic cation transporter; Vesicular acetylcholine transporter

Indexed keywords

AUTOANTIBODY; ACETYLCHOLINE;

ASTHMA; ATHEROSCLEROSIS; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BLADDER DISEASE; BLADDER NECK STENOSIS; CARDIOVASCULAR SYSTEM; CHOLINERGIC SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON CANCER; CYSTIC FIBROSIS; DIGESTIVE SYSTEM; DISEASE COURSE; DNA POLYMORPHISM; ECTOPIC PREGNANCY; FRACTURE HEALING; GENE MUTATION; GENITAL SYSTEM; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE SYSTEM; INFLAMMATORY BOWEL DISEASE; INTEGUMENTARY SYSTEM; KIDNEY DISEASE; LUNG CANCER; MUSCULOSKELETAL SYSTEM; NON NEURONAL CHOLINERGIC SYSTEM; NONHUMAN; OSTEOPOROSIS; OVERACTIVE BLADDER; PANCREATITIS; PEMPHIGUS; PREECLAMPSIA; PRIORITY JOURNAL; PSORIASIS; PUSTULOSIS PALMOPLANTARIS; RESPIRATORY SYSTEM; REVIEW; RHEUMATOID ARTHRITIS; URINARY TRACT; VITILIGO; ACETYLCHOLINE RELEASE; ACETYLCHOLINE SYNTHESIS; ACUTE KIDNEY FAILURE; AUTOSOMAL DISORDER; CHOLINERGIC TRANSMISSION; DISEASES; DRUG TARGETING; GENETIC POLYMORPHISM; GENODERMATOSIS; HEALTH; MAL DE MELEDA; REGULATORY MECHANISM; SYNTHESIS; UTERINE TUBE PREGNANCY;

ACETYLCHOLINE; ANIMALS; AUTOANTIBODIES; DISEASE PROGRESSION; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; POLYMORPHISM, GENETIC; RECEPTORS, CHOLINERGIC;

EID: 84892955085     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000355835     Document Type: Review

References (211)

1. Wessler I, Kirkpatrick CJ, Racke K: The cholinergic 'pitfall': Acetylcholine, a universal cell molecule in biological systems, including humans. Clin Exp Pharmacol Physiol 1999; 26: 198-205.
2. Wessler I, Kilbinger H, Bittinger F, Unger R, Kirkpatrick CJ: The non-neuronal cholinergic system in humans: Expression, function and pathophysiology. Life Sci 2003; 72: 2055-2061.
3. Tucek S: The synthesis of acetylcholine in skeletal muscles of the rat. J Physiol 1982; 322: 53-69.
4. Lips KS, Wunsch J, Zarghooni S, Bschleipfer T, Schukowski K, Weidner W, Wessler I, Schwantes U, Koepsell H, Kummer W: Acetylcholine and molecular components of its synthesis and release machinery in the urothelium. Eur Urol 2007; 51: 1042-1053.
5. Okuda T, Haga T: High-affinity choline transporter. Neurochem Res 2003; 28: 483-488.
6. Haberberger RV, Pfeil U, Lips KS, Kummer W: Expression of the high-affinity choline transporter, CHT1, in the neuronal and nonneuronal cholinergic system of human and rat skin. J Invest Dermatol 2002; 119: 943-948.
7. Pfeil U, Haberberger RV, Lips KS, Eberling L, Grau V, Kummer W: Expression of the highaffinity choline transporter CHT1 in epithelia. Life Sci 2003; 72: 2087-2090.
8. Lips KS, Pfeil U, Reiners K, Rimasch C, Kuchelmeister K, Braun-Dullaeus RC, Haberberger RV, Schmidt R, Kummer W: Expression of the high-affinity choline transporter CHT1 in rat and human arteries. J Histochem Cytochem 2003; 51: 1645-1654.
9. Yamada T, Inazu M, Tajima H, Matsumiya T: Functional expression of choline transporterlike protein 1 (CTL1) in human neuroblastoma cells and its link to acetylcholine synthesis. Neurochem Int 2011; 58: 354-365.
10. Traiffort E, Ruat M, O'Regan S, Meunier FM: Molecular characterization of the family of choline transporter-like proteins and their splice variants. J Neurochem 2005; 92: 1116- 1125.
11. Erickson JD, Varoqui H, Schafer MK, Modi W, Diebler MF, Weihe E, Rand J, Eiden LE, Bonner TI, Usdin TB: Functional identification of a vesicular acetylcholine transporter and its expression from a 'cholinergic' gene locus. J Biol Chem 1994; 269: 21929-21932.
12. Kummer W, Lips KS, Pfeil U: The epithelial cholinergic system of the airways. Histochem Cell Biol 2008; 130: 219-234.
13. Lips KS, Volk C, Schmitt BM, Pfeil U, Arndt P, Miska D, Ermert L, Kummer W, Koepsell H: Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol 2005; 33: 79-88.
14. Koepsell H, Lips K, Volk C: Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007; 24: 1227-1251.
15. Israel M, Dunant Y: Acetylcholine release. Reconstitution of the elementary quantal mechanism. J Physiol (Paris) 1998; 92: 123-128.
16. Hurst R, Rollema H, Bertrand D: Nicotinic acetylcholine receptors: From basic science to therapeutics. Pharmacol Ther 2013; 137: 22- 54.
17. De Jonge WJ, van der Zanden EP, The FO, Bijlsma MF, van Westerloo DJ, Bennink RJ, Berthoud HR, Uematsu S, Akira S, van Den Wijngaard RM, Boeckxstaens GE: Stimulation of the vagus nerve attenuates macrophage activation by activating the JAK2- STAT3 signaling pathway. Nat Immunol 2005; 6: 844-851.
18. Dasgupta P, Kinkade R, Joshi B, Decook C, Haura E, Chellappan S: Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating xiap and survivin. Proc Natl Acad Sci USA 2006; 103: 6332-6337.
19. Fischer J, Bouadjar B, Heilig R, Huber M, Lefevre C, Jobard F, Macari F, Bakija-Konsuo A, Ait-Belkacem F, Weissenbach J, Lathrop M, Hohl D, Prud'homme JF: Mutations in the gene encoding SLURP-1 in mal de Meleda. Hum Mol Genet 2001; 10: 875-880.
20. Wess J: Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol 1996; 10: 69-99.
21. Lanzafame AA, Christopoulos A, Mitchelson F: Cellular signaling mechanisms for muscarinic acetylcholine receptors. Receptors Channels 2003; 9: 241-260.
22. Grando SA, Kist DA, Qi M, Dahl MV: Human keratinocytes synthesize, secrete, and degrade acetylcholine. J Invest Dermatol 1993; 101: 32-36.
23. Grando SA, Pittelkow MR, Schallreuter KU: Adrenergic and cholinergic control in the biology of epidermis: Physiological and clinical significance. J Invest Dermatol 2006; 126: 1948-1965.
24. Wessler I, Reinheimer T, Kilbinger H, Bittinger F, Kirkpatrick CJ, Saloga J, Knop J: Increased acetylcholine levels in skin biopsies of patients with atopic dermatitis. Life Sci 2003; 72: 2169-2172.
25. Raap U, Werfel T, Jaeger B, Schmid-Ott G: Atopic dermatitis and psychological stress (in German). Hautarzt 2003; 54: 925-929.
26. Amano H, Negishi I, Akiyama H, Ishikawa O: Psychological stress can trigger atopic dermatitis in nc/nga mice: An inhibitory effect of corticotropin-releasing factor. Neuropsychopharmacology 2008; 33: 566-573.
27. Curtis BJ, Radek KA: Cholinergic regulation of keratinocyte innate immunity and permeability barrier integrity: New perspectives in epidermal immunity and disease. J Invest Dermatol 2012; 132: 28-42.
28. Schallreuter KU, Elwary SM, Gibbons NC, Rokos H, Wood JM: Activation/deactivation of acetylcholinesterase by H O 2 : More evidence for oxidative stress in vitiligo. Biochem Biophys Res Commun 2004; 315: 502-508.
29. Chimienti F, Hogg RC, Plantard L, Lehmann C, Brakch N, Fischer J, Huber M, Bertrand D, Hohl D: Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of mal de Meleda. Hum Mol Ge net 2003; 12: 3017-3024.
30. Tsuji H, Okamoto K, Matsuzaka Y, Iizuka H, Tamiya G, Inoko H: Slurp-2, a novel member of the human Ly-6 superfamily that is up-regulated in psoriasis vulgaris. Genomics 2003; 81: 26-33.
31. Arredondo J, Chernyavsky AI, Jolkovsky DL, Webber RJ, Grando SA: Slurp-2: A novel cholinergic signaling peptide in human mucocutaneous epithelium. J Cell Physiol 2006; 208: 238-245.
32. Grando SA: Pemphigus autoimmunity: Hypotheses and realities. Autoimmunity 2012; 45: 7-35.
33. Baroni A, Buommino E, Ruocco E, Petrazzuolo M, De Filippis A, Satriano RA, Ruocco V, Cozza V, Tufano MA: Captopril modulates acetylcholinesterase in human keratinocytes. Arch Dermatol Res 2011; 303: 491-497.
34. Hagforsen E: The cutaneous non-neuronal cholinergic system and smoking related dermatoses: Studies of the psoriasis variant palmoplantar pustulosis. Life Sci 2007; 80: 2227- 2234.
35. Ortiz A, Grando SA: Smoking and the skin. Int J Dermatol 2012; 51: 250-262.
36. De Hertog SA, Wensveen CA, Bastiaens MT, Kielich CJ, Berkhout MJ, Westendorp RG, Vermeer BJ, Bouwes Bavinck JN, Leiden Skin Cancer Study: Relation between smoking and skin cancer. J Clin Oncol 2001; 19: 231-238.
37. Anderson LA, Lauria C, Romano N, Brown EE, Whitby D, Graubard BI, Li Y, Messina A, Gafa L, Vitale F, Goedert JJ: Risk factors for classical Kaposi sarcoma in a populationbased case-control study in Sicily. Cancer Epidemiol Biomarkers Prev 2008; 17: 3435- 3443.
38. Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA: Receptor-mediated tobacco toxicity: Cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J 2006; 20: 2093-2101.
39. Chernyavsky AI, Marchenko S, Phillips C, Grando SA: Auto/paracrine nicotinergic peptides participate in cutaneous stress response to wounding. Dermatoendocrinology 2012; 4: 324-330.
40. Buels KS, Fryer AD: Muscarinic receptor antagonists: Effects on pulmonary function. Handb Exp Pharmacol 2012; 208: 317-341.
41. Arias HR, Richards VE, Ng D, Ghafoori ME, Le V, Mousa SA: Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. Int J Biochem Cell Biol 2009; 41: 1441-1451.
42. Klapproth H, Reinheimer T, Metzen J, Munch M, Bittinger F, Kirkpatrick CJ, Hohle KD, Schemann M, Racke K, Wessler I: Non-neuronal acetylcholine, a signalling molecule synthesized by surface cells of rat and man. Naunyn- Schmiedeberg's Arch Pharmacol 1997; 355: 515-523.
43. Carlisle DL, Hopkins TM, Gaither-Davis A, Silhanek MJ, Luketich JD, Christie NA, Siegfried JM: Nicotine signals through muscletype and neuronal nicotinic acetylcholine receptors in both human bronchial epithelial cells and airway fibroblasts. Respir Res 2004; 5: 27.
44. Klein MK, Haberberger RV, Hartmann P, Faulhammer P, Lips KS, Krain B, Wess J, Kummer W, Konig P: Muscarinic receptor subtypes in cilia-driven transport and airway epithelial development. Eur Respir J 2009; 33: 1113-1121.
45. Reinheimer T, Munch M, Bittinger F, Racke K, Kirkpatrick CJ, Wessler I: Glucocorticoids mediate reduction of epithelial acetylcholine content in the airways of rats and humans. Eur J Pharmacol 1998; 349: 277-284.
46. Milara J, Serrano A, Peiro T, Gavalda A, Miralpeix M, Morcillo EJ, Cortijo J: Aclidinium inhibits human lung fibroblast to myofibroblast transition. Thorax 2012; 67: 229-237.
47. Milara J, Serrano A, Peiro T, Artigues E, Gavalda A, Miralpeix M, Morcillo EJ, Cortijo J: Aclidinium inhibits cigarette smoke-induced lung fibroblast-to-myofibroblast transition. Eur Respir J 2013; 41: 1264-1274.
48. Lips KS, Luhrmann A, Tschernig T, Stoeger T, Alessandrini F, Grau V, Haberberger RV, Koepsell H, Pabst R, Kummer W: Down-regulation of the non-neuronal acetylcholine synthesis and release machinery in acute allergic airway inflammation of rat and mouse. Life Sci 2007; 80: 2263-2269.
49. Gwilt CR, Donnelly LE, Rogers DF: The nonneuronal cholinergic system in the airways: An unappreciated regulatory role in pulmonary inflammation Pharmacol Ther 2007; 115: 208-222.
50. The 2004 United States Surgeon General's Report: The health consequences of smoking. New South Wales Publ Health Bull 2004; 15: 107.
51. Singh S, Pillai S, Chellappan S: Nicotinic acetylcholine receptor signaling in tumor growth and metastasis. J Oncol 2011; 2011: 456743.
52. Song P, Spindel ER: Basic and clinical aspects of non-neuronal acetylcholine: Expression of non-neuronal acetylcholine in lung cancer provides a new target for cancer therapy. J Pharmacol Sci 2008; 106: 180-185.
53. Song P, Rekow SS, Singleton CA, Sekhon HS, Dissen GA, Zhou M, Campling B, Lindstrom J, Spindel ER: Choline transporter-like protein 4 (CTL4) links to non-neuronal acetylcholine synthesis. J Neurochem 2013; 126: 451-461.
54. Nakamura T, Fujiwara R, Ishiguro N, Oyabu M, Nakanishi T, Shirasaka Y, Maeda T, Tamai I: Involvement of choline transporter-like proteins, CTL1 and CTL2, in glucocorticoidinduced acceleration of phosphatidylcholine synthesis via increased choline uptake. Biol Pharm Bull 2010; 33: 691-696.
55. Grozio A, Paleari L, Catassi A, Servent D, Cilli M, Piccardi F, Paganuzzi M, Cesario A, Granone P, Mourier G, Russo P: Natural agents targeting the alpha7-nicotinic-receptor in NSCLC: A promising prospective in anti-cancer drug development. Int J Cancer 2008; 122: 1911-1915.
56. Spindel ER: Muscarinic receptor agonists and antagonists: Effects on cancer. Handb Exp Pharmacol 2012; 208: 451-468.
57. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, Manolescu A, Thorleifsson G, Stefansson H, Ingason A, Stacey SN, Bergthorsson JT, Thorlacius S, Gudmundsson J, Jonsson T, Jakobsdottir M, Saemundsdottir J, Olafsdottir O, Gudmundsson LJ, Bjornsdottir G, Kristjansson K, Skuladottir H, Isaksson HJ, Gudbjartsson T, Jones GT, Mueller T, Gottsater A, Flex A, Aben KK, de Vegt F, Mulders PF, Isla D, Vidal MJ, Asin L, Saez B, Murillo L, Blondal T, Kolbeinsson H, Stefansson JG, Hansdottir I, Runarsdottir V, Pola R, Lindblad B, van Rij AM, Dieplinger B, Haltmayer M, Mayordomo JI, Kiemeney LA, Matthiasson SE, Oskarsson H, Tyrfingsson T, Gudbjartsson DF, Gulcher JR, Jonsson S, Thorsteinsdottir U, Kong A, Stefansson K: A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008; 452: 638-642.
58. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia- Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chen C, Goodman G, Field JK, Liloglou T, Xinarianos G, Cassidy A, McLaughlin J, Liu G, Narod S, Krokan HE, Skorpen F, Elvestad MB, Hveem K, Vatten L, Linseisen J, Clavel-Chapelon F, Vineis P, Bueno-de-Mesquita HB, Lund E, Martinez C, Bingham S, Rasmuson T, Hainaut P, Riboli E, Ahrens W, Benhamou S, Lagiou P, Trichopoulos D, Holcatova I, Merletti F, Kjaerheim K, Agudo A, Macfarlane G, Talamini R, Simonato L, Lowry R, Conway DI, Znaor A, Healy C, Zelenika D, Boland A, Delepine M, Foglio M, Lechner D, Matsuda F, Blanche H, Gut I, Heath S, Lathrop M, Brennan P: A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008; 452: 633-637.
59. Chikova A, Bernard HU, Shchepotin IB, Grando SA: New associations of the genetic polymorphisms in nicotinic receptor genes with the risk of lung cancer. Life Sci 2012; 91: 1103-1108.
60. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al: Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 1989; 245: 1066-1073.
61. Wessler I, Bittinger F, Kamin W, Zepp F, Meyer E, Schad A, Kirkpatrick CJ: Dysfunction of the non-neuronal cholinergic system in the airways and blood cells of patients with cystic fibrosis. Life Sci 2007; 80: 2253-2258.
62. Billet A, Luo Y, Balghi H, Hanrahan JW: Role of tyrosine phosphorylation in the muscarinic activation of the cystic fibrosis transmembrane conductance regulator (CFTR). J Biol Chem 2013; 288: 21815-21823.
63. Maouche K, Medjber K, Zahm JM, Delavoie F, Terryn C, Coraux C, Pons S, Cloez-Tayarani I, Maskos U, Birembaut P, Tournier JM: Contribution of alpha7 nicotinic receptor to airway epithelium dysfunction under nicotine exposure. Proc Natl Acad Sci USA 2013; 110: 4099-4104.
64. Greene CM, Ramsay H, Wells RJ, O'Neill SJ, McElvaney NG: Inhibition of Toll-like receptor 2-mediated interleukin-8 production in cystic fibrosis airway epithelial cells via the alpha7-nicotinic acetylcholine receptor. Mediat Inflamm 2010; 2010: 423241.
65. Rana OR, Schauerte P, Kluttig R, Schroder JW, Koenen RR, Weber C, Nolte KW, Weis J, Hoffmann R, Marx N, Saygili E: Acetylcholine as an age-dependent non-neuronal source in the heart. Auton Neurosci Basic Clin 2010; 156: 82-89.
66. Abramochkin DV, Borodinova AA, Rosenshtraukh LV, Nikolsky EE: Both neuronal and non-neuronal acetylcholine take part in non-quantal acetylcholine release in the rat atrium. Life Sci 2012; 91: 1023-1026.
67. Slavikova J, Tucek S: Choline acetyltransferase in the heart of adult rats. Pflugers Arch 1982; 392: 225-229.
68. Dvorakova M, Lips KS, Bruggmann D, Slavikova J, Kuncova J, Kummer W: Developmental changes in the expression of nicotinic acetylcholine receptor alpha-subunits in the rat heart. Cell Tissue Res 2005; 319: 201-209.
69. Shi H, Wang H, Wang Z: Identification and characterization of multiple subtypes of muscarinic acetylcholine receptors and their physiological functions in canine hearts. Mol Pharmacol 1999; 55: 497-507.
70. Harvey RD: Muscarinic receptor agonists and antagonists: Effects on cardiovascular function. Handb Exp Pharmacol 2012; 208: 299- 316.
71. Haberberger RV, Bodenbenner M, Kummer W: Expression of the cholinergic gene locus in pulmonary arterial endothelial cells. Histochem Cell Biol 2000; 113: 379-387.
72. Komori K, Suzuki H: Heterogeneous distribution of muscarinic receptors in the rabbit saphenous artery. Br J Pharmacol 1987; 92: 657-664.
73. Walch L, Gascard JP, Dulmet E, Brink C, Norel X: Evidence for a M(1) muscarinic receptor on the endothelium of human pulmonary veins. Br J Pharmacol 2000; 130: 73-78.
74. Phillips JK, Vidovic M, Hill CE: Variation in mRNA expression of alpha-adrenergic, neurokinin and muscarinic receptors amongst four arteries of the rat. J Auton Nerv Syst 1997; 62: 85-93.
75. Kirkpatrick CJ, Bittinger F, Unger RE, Kriegsmann J, Kilbinger H, Wessler I: The non-neuronal cholinergic system in the endothelium: Evidence and possible pathobiological significance. Jpn J Pharmacol 2001; 85: 24-28.
76. Li XW, Wang H: Non-neuronal nicotinic alpha receptor, a new endothelial target for revascularization. Life Sci 2006; 78: 1863- 1870.
77. Heeschen C, Weis M, Aicher A, Dimmeler S, Cooke JP: A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest 2002; 110: 527-536.
78. Wu JC, Chruscinski A, De Jesus Perez VA, Singh H, Pitsiouni M, Rabinovitch M, Utz PJ, Cooke JP: Cholinergic modulation of angiogenesis: Role of the nicotinic acetylcholine receptor. J Cell Biochem 2009; 108: 433-446.
79. Kakinuma Y, Furihata M, Akiyama T, Arikawa M, Handa T, Katare RG, Sato T: Donepezil, an acetylcholinesterase inhibitor against Alzheimer's dementia, promotes angiogenesis in an ischemic hindlimb model. J Mol Cell Cardiol 2010; 48: 680-693.
80. Ferdinandy P, Schulz R, Baxter GF: Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007; 59: 418-458.
81. Pan Z, Guo Y, Qi H, Fan K, Wang S, Zhao H, Fan Y, Xie J, Guo F, Hou Y, Wang N, Huo R, Zhang Y, Liu Y, Du Z: M3 subtype of muscarinic acetylcholine receptor promotes cardioprotection via the suppression of miR-376b- 5p. PloS One 2012; 7:e32571.
82. Lee J, Cooke JP: Nicotine and pathological angiogenesis. Life Sci 2012; 91: 1058-1064.
83. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, Tsao PS, Johnson FL, Cooke JP: Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001; 7: 833-839.
84. Nguyen VT, Hall LL, Gallacher G, Ndoye A, Jolkovsky DL, Webber RJ, Buchli R, Grando SA: Choline acetyltransferase, acetylcholinesterase, and nicotinic acetylcholine receptors of human gingival and esophageal epithelia. J Dent Res 2000; 79: 939-949.
85. Saegusa Y, Takeda H, Muto S, Oridate N, Nakagawa K, Sadakane C, Nahata M, Harada Y, Iizuka M, Hattori T, Asaka M: Decreased motility of the lower esophageal sphincter in a rat model of gastroesophageal reflux disease may be mediated by reductions of serotonin and acetylcholine signaling. Biol Pharm Bull 2011; 34: 704-711.
86. Wolf-Johnston AS, Hanna-Mitchell AT, Buffington CA, Shinde S, Roppolo JR, Mayer E, Birder LA: Alterations in the non-neuronal acetylcholine synthesis and release machinery in esophageal epithelium. Life Sci 2012; 91: 1065-1069.
87. Harrington AM, Hutson JM, Southwell BR: Cholinergic neurotransmission and muscarinic receptors in the enteric nervous system. Prog Histochem Cytochem 2010; 44: 173-202.
88. Ruggieri MR, Braverman AS: Gastric body cholinergic contractile signal transduction in M2 and M3 receptor knockout mice. J Receptor Signal Transduct Res 2013; 33: 249-254.
89. Xie G, Drachenberg C, Yamada M, Wess J, Raufman JP: Cholinergic agonist-induced pepsinogen secretion from murine gastric chief cells is mediated by M1 and M3 muscarinic receptors. Am J Physiol Gastrointest Liver Physiol 2005; 289:G521-G529.
90. Aihara T, Nakamura Y, Taketo MM, Matsui M, Okabe S: Cholinergically stimulated gastric acid secretion is mediated by M(3) and M(5) but not M(1) muscarinic acetylcholine receptors in mice. Am J Physiol Gastrointest Liver Physiol 2005; 288:G1199-G1207.
91. Raufman JP: Peptic activity and gastroduodenal mucosal damage. Yale J Biol Med 1996; 69: 85-90.
92. Nathanson NM: Synthesis, trafficking, and localization of muscarinic acetylcholine receptors. Pharmacol Ther 2008; 119: 33-43.
93. Cameron HL, Perdue MH: Muscarinic acetylcholine receptor activation increases trans cellular transport of macromolecules across mouse and human intestinal epithelium in vitro. Neurogastroenterol Motil 2007; 19: 47-56.
94. Gautron L, Rutkowski JM, Burton MD, Wei W, Wan Y, Elmquist JK: Neuronal and nonneuronal cholinergic structures in the mouse gastrointestinal tract and spleen. J Comp Neurol 2013; 521: 3741-3767.
95. Yajima T, Inoue R, Matsumoto M, Yajima M: Non-neuronal release of ACh plays a key role in secretory response to luminal propionate in rat colon. J Physiol 2011; 589: 953- 962.
96. Yang WL, Frucht H: Cholinergic receptor up-regulates COX-2 expression and prostaglandin E(2) production in colon cancer cells. Carcinogenesis 2000; 21: 1789-1793.
97. Raufman JP, Cheng K, Saxena N, Chahdi A, Belo A, Khurana S, Xie G: Muscarinic receptor agonists stimulate matrix metalloproteinase 1-dependent invasion of human colon cancer cells. Biochem Biophys Res Commun 2011; 415: 319-324.
98. Pettersson A, Nilsson L, Nylund G, Khorram- Manesh A, Nordgren S, Delbro DS: Is acetylcholine an autocrine/paracrine growth factor via the nicotinic alpha7-receptor subtype in the human colon cancer cell line HT- 29 Eur J Pharmacol 2009; 609: 27-33.
99. Cucina A, Dinicola S, Coluccia P, Proietti S, D'Anselmi F, Pasqualato A, Bizzarri M: Nicotine stimulates proliferation and inhibits apoptosis in colon cancer cell lines through activation of survival pathways. J Surg Res 2012; 178: 233-241.
100. Pettersson A, Nordlander S, Nylund G, Khorram-Manesh A, Nordgren S, Delbro DS: Expression of the endogenous, nicotinic acetylcholine receptor ligand, SLURP-1, in human colon cancer. Auton Autac Pharmacol 2008; 28: 109-116.
101. Maharshak N, Shenhar-Tsarfaty S, Aroyo N, Orpaz N, Guberman I, Canaani J, Halpern Z, Dotan I, Berliner S, Soreq H: MicroRNA-132 modulates cholinergic signaling and inflammation in human inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 1346- 1353.
102. Hilsden RJ, Hodgins DC, Timmer A, Sutherland LR: Helping patients with Crohn's disease quit smoking. Am J Gastroenterol 2000; 95: 352-358.
103. De Jonge WJ, Ulloa L: The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 2007; 151: 915-929.
104. Jonsson M, Norrgard O, Forsgren S: Presence of a marked nonneuronal cholinergic system in human colon: Study of normal colon and colon in ulcerative colitis. Inflamm Bowel Dis 2007; 13: 1347-1356.
105. Richardson CE, Morgan JM, Jasani B, Green JT, Rhodes J, Williams GT, Lindstrom J, Wonnacott S, Peel S, Thomas GA: Effect of smoking and transdermal nicotine on colonic nicotinic acetylcholine receptors in ulcerative colitis. Q J Med 2003; 96: 57-65.
106. Ghia JE, Blennerhassett P, Deng Y, Verdu EF, Khan WI, Collins SM: Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology 2009; 136: 2280-2288.
107. Lakhan SE, Kirchgessner A: Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J Transl Med 2011; 9: 129.
108. Orr-Urtreger A, Kedmi M, Rosner S, Karmeli F, Rachmilewitz D: Increased severity of experimental colitis in alpha 5 nicotinic acetylcholine receptor subunit-deficient mice. Neuroreport 2005; 16: 1123-1127.
109. Gautam D, Han SJ, Heard TS, Cui Y, Miller G, Bloodworth L, Wess J: Cholinergic stimulation of amylase secretion from pancreatic acinar cells studied with muscarinic acetylcholine receptor mutant mice. J Pharmacol Exp Ther 2005; 313: 995-1002.
110. Chowdhury P, Bose C, Udupa KB: Nicotineinduced proliferation of isolated rat pancreatic acinar cells: Effect on cell signalling and function. Cell Prolif 2007; 40: 125-141.
111. Phillips PA, Yang L, Shulkes A, Vonlaufen A, Poljak A, Bustamante S, Warren A, Xu Z, Guilhaus M, Pirola R, Apte MV, Wilson JS: Pancreatic stellate cells produce acetylcholine and may play a role in pancreatic exocrine secretion. Proc Natl Acad Sci USA 2010; 107: 17397-17402.
112. Gautam D, Han SJ, Hamdan FF, Jeon J, Li B, Li JH, Cui Y, Mears D, Lu H, Deng C, Heard T, Wess J: A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab 2006; 3: 449- 461.
113. Rodriguez-Diaz R, Dando R, Jacques-Silva MC, Fachado A, Molina J, Abdulreda MH, Ricordi C, Roper SD, Berggren PO, Caicedo A: Alpha cells secrete acetylcholine as a nonneuronal paracrine signal priming beta cell function in humans. Nat Med 2011; 17: 888- 892.
114. Talamini G, Bassi C, Falconi M, Sartori N, Salvia R, Rigo L, Castagnini A, Di Francesco V, Frulloni L, Bovo P, Vaona B, Angelini G, Vantini I, Cavallini G, Pederzoli P: Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer. Dig Dis Sci 1999; 44: 1303-1311.
115. Samuel I, Zaheer S, Fisher RA, Zaheer A: Cholinergic receptor induction and JNK activation in acute pancreatitis. Am J Surg 2003; 186: 569-574.
116. Maeda S, Jun JG, Kuwahara-Otani S, Tanaka K, Hayakawa T, Seki M: Non-neuronal expression of choline acetyltransferase in the rat kidney. Life Sci 2011; 89: 408-414.
117. Vander AJ: Effects of acetylcholine, atropine, and physostigmine on renal function in the dog. Am J Physiol 1964; 206: 492-498.
118. Harvey RB: Effects of acetylcholine infused into renal artery of dogs. Am J Physiol 1966; 211: 487-492.
119. McArdle S, Garg LC, Crews FT: Cholinergic receptors in renal medullary collecting duct cells. J Pharmacol Exp Ther 1989; 248: 12-16.
120. Mohuczy-Dominiak D, Garg LC: Characterization of cholinergic receptors in Madin- Darby canine kidney cells. J Am Soc Nephrol 1992; 3: 170-181.
121. Nadler LS, Kumar G, Hinds TR, Migeon JC, Nathanson NM: Asymmetric distribution of muscarinic acetylcholine receptors in Madin- Darby canine kidney cells. Am J Physiol 1999; 277:C1220-C1228.
122. Nitschke R, Henger A, Ricken S, Muller V, Kottgen M, Bek M, Pavenstadt H: Acetylcholine increases the free intracellular calcium concentration in podocytes in intact rat glomeruli via muscarinic M(5) receptors. J Am Soc Nephrol 2001; 12: 678-687.
123. Robey RB, Ruiz OS, Baniqued J, Mahmud D, Espiritu DJ, Bernardo AA, Arruda JA: SFKs, Ras, and the classic MAPK pathway couple muscarinic receptor activation to increased Na-HCO(3) cotransport activity in renal epithelial cells. Am J Physiol Renal Physiol 2001; 280:F844-F850.
124. Rezonzew G, Chumley P, Feng W, Hua P, Siegal GP, Jaimes EA: Nicotine exposure and the progression of chronic kidney disease: Role of the alpha7-nicotinic acetylcholine receptor. Am J Physiol Renal Physiol 2012; 303:F304-F312.
125. el-Mas MM, el-Gowilly SM, Gohar EY, Ghazal AR, Abdel-Rahman AA: Estrogen dependence of the renal vasodilatory effect of nicotine in rats: Role of alpha7 nicotinic cholinergic receptor/eNOS signaling. Life Sci 2011; 88: 187-193.
126. Yeboah MM, Xue X, Javdan M, Susin M, Metz CN: Nicotinic acetylcholine receptor expression and regulation in the rat kidney after ischemia-reperfusion injury. Am J Physiol Renal Physiol 2008; 295:F654-F661.
127. Sellers DJ, Chess-Williams R: Muscarinic agonists and antagonists: Effects on the urinary bladder. Handb Exp Pharmacol 2012; 208: 375-400.
128. Yoshida M, Inadome A, Maeda Y, Satoji Y, Masunaga K, Sugiyama Y, Murakami S: Nonneuronal cholinergic system in human bladder urothelium. Urology 2006; 67: 425-430.
129. Hanna-Mitchell AT, Beckel JM, Barbadora S, Kanai AJ, de Groat WC, Birder LA: Nonneuronal acetylcholine and urinary bladder urothelium. Life Sci 2007; 80: 2298-2302.
130. Bschleipfer T, Schukowski K, Weidner W, Grando SA, Schwantes U, Kummer W, Lips KS: Expression and distribution of cholinergic receptors in the human urothelium. Life Sci 2007; 80: 2303-2307.
131. Zarghooni S, Wunsch J, Bodenbenner M, Bruggmann D, Grando SA, Schwantes U, Wess J, Kummer W, Lips KS: Expression of muscarinic and nicotinic acetylcholine receptors in the mouse urothelium. Life Sci 2007; 80: 2308-2313.
132. Chatterjee PK, Yeboah MM, Dowling O, Xue X, Powell SR, Al-Abed Y, Metz CN: Nicotinic acetylcholine receptor agonists attenuate septic acute kidney injury in mice by suppressing inflammation and proteasome activity. PloS One 2012; 7:e35361.
133. Yeboah MM, Xue X, Duan B, Ochani M, Tracey KJ, Susin M, Metz CN: Cholinergic agonists attenuate renal ischemia-reperfusion injury in rats. Kidney Int 2008; 74: 62-69.
134. Sadis C, Teske G, Stokman G, Kubjak C, Claessen N, Moore F, Loi P, Diallo B, Barvais L, Goldman M, Florquin S, Le Moine A: Nicotine protects kidney from renal ischemia/reperfusion injury through the cholinergic anti-inflammatory pathway. PloS One 2007; 2:e469.
135. Hua P, Feng W, Ji S, Raij L, Jaimes EA: Nicotine worsens the severity of nephropathy in diabetic mice: Implications for the progression of kidney disease in smokers. Am J Physiol Renal Physiol 2010; 299:F732-F739.
136. Mercado C, Jaimes EA: Cigarette smoking as a risk factor for atherosclerosis and renal disease: Novel pathogenic insights. Curr Hypertens Rep 2007; 9: 66-72.
137. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A, Standardisation Subcommittee of the International Continence Study: The standardisation of terminology of lower urinary tract function: Report from the standardisation subcommittee of the international continence society. Neurourol Urodyn 2002; 21: 167-178.
138. Andersson KE, Yoshida M: Antimuscarinics and the overactive detrusor - which is the main mechanism of action Eur Urol 2003; 43: 1-5.
139. Yamaguchi O: Antimuscarinics and overactive bladder: Other mechanism of action. Neurourol Urodyn 2010; 29: 112-115.
140. Andersson KE: Antimuscarinic mechanisms and the overactive detrusor: An update. Eur Urol 2011; 59: 377-386.
141. Wein AJ: Re: Antimuscarinic mechanisms and the overactive detrusor: An update. J Urol 2012; 188: 888-889.
142. Ochodnicky P, Uvelius B, Andersson KE, Michel MC: Autonomic nervous control of the urinary bladder. Acta Physiol (Oxf) 2013; 207: 16-33.
143. Bschleipfer T, Weidner W, Kummer W, Lips KS: Does bladder outlet obstruction alter the non-neuronal cholinergic system of the human urothelium Life Sci 2012; 91: 1082-1086.
144. Bschleipfer T, Nandigama R, Moeller S, Illig C, Weidner W, Kummer W: Bladder outlet obstruction influences mRNA expression of cholinergic receptors on sensory neurons in mice. Life Sci 2012; 91: 1077-1081.
145. Weber S, Thiele H, Mir S, Toliat MR, Sozeri B, Reutter H, Draaken M, Ludwig M, Altmuller J, Frommolt P, Stuart HM, Ranjzad P, Hanley NA, Jennings R, Newman WG, Wilcox DT, Thiel U, Schlingmann KP, Beetz R, Hoyer PF, Konrad M, Schaefer F, Nurnberg P, Woolf AS: Muscarinic acetylcholine receptor M3 mutation causes urinary bladder disease and a prune-belly-like syndrome. Am J Hum Genet 2011; 89: 668-674.
146. Fritz S, Wessler I, Breitling R, Rossmanith W, Ojeda SR, Dissen GA, Amsterdam A, Mayerhofer A: Expression of muscarinic receptor types in the primate ovary and evidence for nonneuronal acetylcholine synthesis. J Clin Endocrinol Metab 2001; 86: 349-354.
147. Wessler I, Roth E, Deutsch C, Brockerhoff P, Bittinger F, Kirkpatrick CJ, Kilbinger H: Release of non-neuronal acetylcholine from the isolated human placenta is mediated by organic cation transporters. Br J Pharmacol 2001; 134: 951-956.
148. Steffl M, Schweiger M, Wessler I, Kunz L, Mayerhofer A, Amselgruber WM: Nonneuronal acetylcholine and choline acetyltransferase in oviductal epithelial cells of cyclic and pregnant pigs. Anat Embryol 2006; 211: 685-690.
149. Kitazawa T, Hirama R, Masunaga K, Nakamura T, Asakawa K, Cao J, Teraoka H, Unno T, Komori S, Yamada M, Wess J, Taneike T: Muscarinic receptor subtypes involved in carbachol-induced contraction of mouse uterine smooth muscle. Naunyn-Schmiedeberg's Arch Pharmacol 2008; 377: 503-513.
150. Sastry BV: Human placental cholinergic system. Biochem Pharmacol 1997; 53: 1577- 1586.
151. Pavia J, Munoz M, Jimenez E, Martos F, Gonzalez-Correa JA, De la Cruz JP, Garcia V, Sanchez de la Cuesta F: Pharmacological characterization and distribution of muscarinic receptors in human placental syncytiotrophoblast brush-border and basal plasma membranes. Eur J Pharmacol 1997; 320: 209- 214.
152. Wolff M, Noreikat K, Ibanez-Tallon I, Lips KS, Kolle S, Kummer W: Cholinergic receptors in the murine oviduct: Inventory and coupling to intracellular calcium concentration. Life Sci 2012; 91: 1003-1008.
153. Shaw JLV, Oliver E, Lee K-F, Entrican G, Jabbour HN, Critchley HOD, Horne AW: Cotinine exposure increases fallopian tube PROKR1 expression via nicotinic AChR-7: A potential mechanism explaining the link between smoking and tubal ectopic pregnancy. Am J Pathol 2010; 177: 2509-2515.
154. Sekhon HS, Jia Y, Raab R, Kuryatov A, Pankow JF, Whitsett JA, Lindstrom J, Spindel ER: Prenatal nicotine increases pulmonary alpha7 nicotinic receptor expression and alters fetal lung development in monkeys. J Clin Invest 1999; 103: 637-647.
155. Wongtrakool C, Grooms K, Ping XD, Rivera H, Ward J, Roser-Page S, Roman J, Brown LA, Gauthier TW: In utero nicotine exposure promotes M2 activation in neonatal mouse alveolar macrophages. Pediatr Res 2012; 72: 147-153.
156. Mimura K, Tomimatsu T, Sharentuya N, Tskitishvili E, Kinugasa-Taniguchi Y, Kanagawa T, Kimura T: Nicotine restores endothelial dysfunction caused by excess SFLT1 and SENG in an in vitro model of preeclamptic vascular endothelium: A possible therapeutic role of nicotinic acetylcholine receptor (nAChR) agonists for preeclampsia. Am J Obstet Gynecol 2010; 202: 464 e461-e466.
157. Dowling O, Rochelson B, Way K, Al-Abed Y, Metz CN: Nicotine inhibits cytokine production by placenta cells via NFkappaB: Potential role in pregnancy-induced hypertension. Mol Med 2007; 13: 576-583.
158. Schirmer SU, Eckhardt I, Lau H, Klein J, De- Graaf YC, Lips KS, Pineau C, Gibbins IL, Kummer W, Meinhardt A, Haberberger RV: The cholinergic system in rat testis is of nonneuronal origin. Reproduction (Cambridge) 2011; 142: 157-166.
159. Ibanez CF, Pelto-Huikko M, Soder O, Ritzen EM, Hersh LB, Hokfelt T, Persson H: Expression of choline acetyltransferase mRNA in spermatogenic cells results in an accumulation of the enzyme in the postacrosomal region of mature spermatozoa. Proc Natl Acad Sci USA 1991; 88: 3676-3680.
160. Ventura S, Pennefather J, Mitchelson F: Cholinergic innervation and function in the prostate gland. Pharmacol Ther 2002; 94: 93- 112.
161. White CW, Short JL, Haynes JM, Matsui M, Ventura S: Contractions of the mouse prostate elicited by acetylcholine are mediated by M(3) muscarinic receptors. J Pharmacol Exp Ther 2011; 339: 870-877.
162. Nieto-Ceron S, Vargas-Lopez H, Perez-Albacete M, Tovar-Zapata I, Martinez- Hernandez P, Rodriguez-Lopez JN, Cabezas- Herrera J: Analysis of cholinesterases in human prostate and sperm: Implications in cancer and fertility. Chemicobiol Interact 2010; 187: 432-435.
163. Bray C, Son JH, Kumar P, Meizel S: Mice deficient in chRNA7, a subunit of the nicotinic acetylcholine receptor, produce sperm with impaired motility. Biol Reprod 2005; 73: 807-814.
164. Dwivedi C, Long NJ: Effect of cholinergic agents on human spermatozoa motility. Biochem Med Metab Biol 1989; 42: 66-70.
165. Avellar MC, Siu ER, Yasuhara F, Marostica E, Porto CS: Muscarinic acetylcholine receptor subtypes in the male reproductive tract: Expression and function in rat efferent ductules and epididymis. J Mol Neurosci 2010; 40: 127-134.
166. Kawashima K, Fujii T: Extraneuronal cholinergic system in lymphocytes. Pharmacol Ther 2000; 86: 29-48.
167. Kawashima K, Kajiyama K, Fujimoto K, Oohata H, Suzuki T: Presence of acetylcholine in blood and its localization in circulating mononuclear leukocytes of humans. Biogenic Amines 1993; 9: 251-258.
168. Kawashima K, Fujii T, Moriwaki Y, Misawa H: Critical roles of acetylcholine and the muscarinic and nicotinic acetylcholine receptors in the regulation of immune function. Life Sci 2012; 91: 1027-1032.
169. Fujii T, Yamada S, Watanabe Y, Misawa H, Tajima S, Fujimoto K, Kasahara T, Kawashima K: Induction of choline acetyltransferase mRNA in human mononuclear leukocytes stimulated by phytohemagglutinin, a T-cell activator. J Neuroimmunol 1998; 82: 101-107.
170. Fujii T, Takada-Takatori Y, Horiguchi K, Kawashima K: Mediatophore regulates acetylcholine release from T cells. J Neuroimmunol 2012; 244: 16-22.
171. Sato KZ, Fujii T, Watanabe Y, Yamada S, Ando T, Kazuko F, Kawashima K: Diversity of mRNA expression for muscarinic acetylcholine receptor subtypes and neuronal nicotinic acetylcholine receptor subunits in human mononuclear leukocytes and leukemic cell lines. Neurosci Lett 1999; 266: 17-20.
172. Zimring JC, Kapp LM, Yamada M, Wess J, Kapp JA: Regulation of CD8+ cytolytic T lymphocyte differentiation by a cholinergic pathway. J Neuroimmunol 2005; 164: 66-75.
173. Fujii YX, Tashiro A, Arimoto K, Fujigaya H, Moriwaki Y, Misawa H, Fujii T, Matsui M, Kasahara T, Kawashima K: Diminished antigen- specific IgG1 and interleukin-6 production and acetylcholinesterase expression in combined M1 and M5 muscarinic acetylcholine receptor knockout mice. J Neuroimmunol 2007; 188: 80-85.
174. Sandberg G: Leukocyte mobilization from the guinea pig spleen by muscarinic cholinergic stimulation. Experientia 1994; 50: 40-43.
175. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ: Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003; 421: 384-388.
176. Borovikova LV, Ivanova S, Nardi D, Zhang M, Yang H, Ombrellino M, Tracey KJ: Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton Neurosci Basic Clin 2000; 85: 141-147.
177. Tracey KJ: Reflex control of immunity. Nat Rev Immunol 2009; 9: 418-428.
178. Xu ZP, Yang K, Xu GN, Zhu L, Hou LN, Zhang WH, Chen HZ, Cui YY: Role of M3 mAChR in in vivo and in vitro models of LPS-induced inflammatory response. Int Immunopharmacol 2012; 14: 320-327.
179. Kawashima K, Fujii T: The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci 2003; 74: 675-696.
180. Lee BH, Gauna AE, Perez G, Park YJ, Pauley KM, Kawai T, Cha S: Autoantibodies against muscarinic type 3 receptor in Sjogren's syndrome inhibit aquaporin 5 trafficking. PloS One 2013; 8:e53113.
181. Fujimoto K, Matsui M, Fujii T, Kawashima K: Decreased acetylcholine content and choline acetyltransferase mRNA expression in circulating mononuclear leukocytes and lymphoid organs of the spontaneously hypertensive rat. Life Sci 2001; 69: 1629-1638.
182. Valdes-Ferrer SI, Crispin JC, Belaunzaran PF, Cantu-Brito CG, Sierra-Madero J, Alcocer- Varela J: Acetylcholine-esterase inhibitor pyridostigmine decreases T cell overactivation in patients infected by HIV. AIDS Res Hum Retroviruses 2009; 25: 749-755.
183. Inkson CA, Brabbs AC, Grewal TS, Skerry TM, Genever PG: Characterization of acetylcholinesterase expression and secretion during osteoblast differentiation. Bone 2004; 35: 819-827.
184. En-Nosse M, Hartmann S, Trinkaus K, Alt V, Stigler B, Heiss C, Kilian O, Schnettler R, Lips KS: Expression of non-neuronal cholinergic system in osteoblast-like cells and its involvement in osteogenesis. Cell Tissue Res 2009; 338: 203-215.
185. Eimar H, Tamimi I, Murshed M, Tamimi F: Cholinergic regulation of bone. J Musculoskelet Neuronal Interact 2013; 13: 124- 132.
186. Bajayo A, Bar A, Denes A, Bachar M, Kram V, Attar-Namdar M, Zallone A, Kovacs KJ, Yirmiya R, Bab I: Skeletal parasympathetic innervation communicates central IL-1 signals regulating bone mass accrual. Proc Natl Acad Sci USA 2012; 109: 15455- 15460.
187. Shi Y, Oury F, Yadav VK, Wess J, Liu XS, Guo XE, Murshed M, Karsenty G: Signaling through the M3 muscarinic receptor favors bone mass accrual by decreasing sympathetic activity. Cell Metab 2010; 11: 231-238.
188. Kliemann K, Kneffel M, Bergen I, Kampschulte M, Langheinrich AC, Durselen L, Ignatius A, Kilian O, Schnettler R, Lips KS: Quantitative analyses of bone composition in acetylcholine receptor M3R and alpha7 knockout mice. Life Sci 2012; 91: 997- 1002.
189. Hamann M, Chamoin MC, Portalier P, Bern heim L, Baroffio A, Widmer H, Bader CR, Ternaux JP: Synthesis and release of an acetylcholine-like compound by human myoblasts and myotubes. J Physiol 1995; 489: 791-803.
190. Danielson P, Alfredson H, Forsgren S: Immunohistochemical and histochemical findings favoring the occurrence of autocrine/paracrine as well as nerve-related cholinergic effects in chronic painful patellar tendon tendinosis. Microsc Res Tech 2006; 69: 808- 819.
191. Danielson P, Andersson G, Alfredson H, Forsgren S: Extensive expression of markers for acetylcholine synthesis and of M2 receptors in tenocytes in therapy-resistant chronic painful patellar tendon tendinosis - a pilot study. Life Sci 2007; 80: 2235-2238.
192. Bjur D, Danielson P, Alfredson H, Forsgren S: Presence of a non-neuronal cholinergic system and occurrence of up- and downregulation in expression of M2 muscarinic acetylcholine receptors: New aspects of importance regarding Achilles tendon tendinosis (tendinopathy). Cell Tissue Res 2008; 331: 385-400.
193. Spang C, Alfredson H, Ferguson M, Roos B, Bagge J, Forsgren S: The plantaris tendon in association with mid-portion Achilles tendinosis - tendinosis-like morphological features and presence of a non-neuronal cholinergic system. Histol Histopathol 2013; 28: 623-632.
194. Deng Y, Li T-Q, Yan Y-E, Magdalou J, Wang H, Chen L-B: Effect of nicotine on chondrogenic differentiation of rat bone marrow mesenchymal stem cells in alginate bead culture. Bio-Medical Materials and Engineering 2012; 22: 81-87.
195. Ying X, Zhang W, Cheng S, Nie P, Cheng X, Shen Y, Wang W, Xue E, Chen Q, Kou D, Peng L, Zhang Y, Lu C: Nicotine-induced chondrogenic differentiation of human bone marrow stromal cells in vitro. Knee Surg Sports Traumatol Arthrosc 2012; 20: 2329-2336.
196. Grimsholm O, Rantapaa-Dahlqvist S, Dalen T, Forsgren S: Unexpected finding of a marked non-neuronal cholinergic system in human knee joint synovial tissue. Neurosci Lett 2008; 442: 128-133.
197. Forsgren S: Presence of ChAT mRNA and a very marked 7nAChR immunoreaction in the synovial lining layer of the knee joint. Life Sci 2012; 91: 1043-1047.
198. Schubert J, Beckmann J, Hartmann S, Morhenn HG, Szalay G, Heiss C, Schnettler R, Lips KS: Expression of the non-neuronal cholinergic system in human knee synovial tissue from patients with rheumatoid arthritis and osteoarthritis. Life Sci 2012; 91: 1048- 1052.
199. Kapoor SR, Filer A, Fitzpatrick MA, Fisher BA, Taylor PC, Buckley CD, McInnes IB, Raza K, Young SP: Metabolic profiling predicts response to anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis. Arthritis Rheum 2013; 65: 1448- 1456.
200. Waldburger JM, Boyle DL, Pavlov VA, Tracey KJ, Firestein GS: Acetylcholine regulation of synoviocyte cytokine expression by the alpha7 nicotinic receptor. Arthritis Rheum 2008; 58: 3439-3449.
201. Van Maanen MA, Lebre MC, van der Poll T, LaRosa GJ, Elbaum D, Vervoordeldonk MJ, Tak PP: Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum 2009; 60: 114-122.
202. Lindblad SS, Mydel P, Jonsson IM, Senior RM, Tarkowski A, Bokarewa M: Smoking and nicotine exposure delay development of collagen-induced arthritis in mice. Arthritis Res Ther 2009; 11:R88.
203. Yu H, Yang YH, Rajaiah R, Moudgil KD: Nicotine-induced differential modulation of autoimmune arthritis in the Lewis rat involves changes in interleukin-17 and anticyclic citrullinated peptide antibodies. Arthritis Rheum 2011; 63: 981-991.
204. Van Maanen MA, Stoof SP, Larosa GJ, Vervoordeldonk MJ, Tak PP: Role of the cholinergic nervous system in rheumatoid arthritis: Aggravation of arthritis in nicotinic acetylcholine receptor alpha7 subunit gene knockout mice. Annals Rheum Dis 2010; 69: 1717-1723.
205. Westman M, Saha S, Morshed M, Lampa J: Lack of acetylcholine nicotine alpha 7 receptor suppresses development of collagen-induced arthritis and adaptive immunity. Clin Exp Immunol 2010; 162: 62-67.
206. Buerkle H, Boschin M, Marcus MA, Brodner G, Wusten R, Van Aken H: Central and peripheral analgesia mediated by the acetylcholinesterase- inhibitor neostigmine in the rat inflamed knee joint model. Anesth Analg 1998; 86: 1027-1032.
207. Dogan N, Erdem AF, Erman Z, Kizilkaya M: The effects of bupivacaine and neostigmine on articular cartilage and synovium in the rabbit knee joint. J Int Med Res 2004; 32: 513-519.
208. Rowley TJ, McKinstry A, Greenidge E, Smith W, Flood P: Antinociceptive and antiinflammatory effects of choline in a mouse model of postoperative pain. Br J Anaesthesia 2010; 105: 201-207.
209. McIntosh JM, Absalom N, Chebib M, Elgoyhen AB, Vincler M: Alpha9 nicotinic acetylcholine receptors and the treatment of pain. Biochem Pharmacol 2009; 78: 693-702.
210. Baek YH, Choi DY, Yang HI, Park DS: Analgesic effect of electroacupuncture on inflammatory pain in the rat model of collagen- induced arthritis: Mediation by cholinergic and serotonergic receptors. Brain Res 2005; 1057: 181-185.
211. Motta PG, Perez AC, Alves DP, Duarte ID: Modulation of peripheral inflammatory pain thresholds by M(1) and nicotinic receptor antagonists. Pharmacology 2011; 88: 309-315.